H2020Индивидуална стипендия2015–2017

FUNFIT · Fungal resistance to antifungals is promoted by cell heterogeneity

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-06-01 → 2017-05-31
Финансиране от ЕС
195 455 €
Участници
1
Схема
MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Разнообразието между клетките на гъбичките, като Aspergillus fumigatus, може да помага на някои от тях да оцеляят след лечение с антифунгални препарати. Разбирането на този механизъм е важно, защото смъртността от гъбични инфекции е висока, а устойчивостта към лекарствата нараства.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Fungal resistance to antifungals is promoted by cell heterogeneity

Problem The main hypothesis that I will test is that fungal cell heterogeneity provides subpopulations of cells with greater fitness to resist antifungal treatment. Importance for society The number of people who die from fungal infections (~2 million p.a.) is greater than the numbers that die from tuberculosis or malaria (1.3 and 0.63 million p.a., respectively). Furthermore, ~25% of the world’s population at any one time suffer from superficial fungal infections of skin and nails. The lung disease aspergillosis, caused by Aspergillus fumigatus, is one of the most common invasive fungal diseases and mortality rates are nearly 100% when untreated and as high as 50% when treated. Individuals most susceptible to invasive fungal diseases are those that are immunocompromised (e.g. patients with AIDS or undergoing immunosuppressive drug treatment). There are only 3 major classes of commercial antifungal drugs available to treat invasive fungal diseases: azoles (which inhibit ergosterol synthesis), polyenes (which target ergosterol in the plasma membrane), and echinocandins (which inhibit β-1,3-glucan synthesis in the cell wall). Resistance of A. fumigatus and other fungal pathogens against antifungal drugs is increasing. This is particularly significant with regard to the azoles that are the first-line treatment of invasive fungal diseases. A significant cause of this has been attributed to the widespread agricultural use of azole fungicides. Different resistance mechanisms against azoles and other antifungals have been reported including: exclusion or active efflux from the fungal cell; overproduction of the drug target; and structural alterations of the drug target by mutations. A mechanistic understanding of antifungal resistance and discovery of new antifungals is of critical importance to combat the very serious problem of invasive fungal diseases. Objectives (1) Determine which features of three distinct fungal cell types contribute to cell heterogeneity; (2) Determine which cell types and subpopulations of these cells show highest resistance or survival against antifungals; and (3) Determine the roles of septal plugging and cell ploidy in the mechanistic basis of fungal cell heterogeneity. Conclusions (1) Cell heterogeneity can be observed in different cell types and for many different characteristics of cells (e.g. cell wall composition) (2) Cell heterogeneity is dynamic, but persistent in successive cell generations (3) My data suggests that cell heterogeneity impacts antifungal treatment (4) Cell heterogeneity influences phagocytosis of spores by immune cells (macrophages) (5) Our data provides evidence that epigenetics are involved in the emergence of cell heterogeneity

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The number of people who die from fungal infections is estimated to be equivalent to or greater than the numbers that die from either tuberculosis or malaria. There are only 3 classes of antifungal drugs available to treat these invasive diseases and resistance against these drugs is increasing. In this study I will investigate how antifungal resistance is impacted by cell heterogeneity in the pathogenic fungus Aspergillus fumigatus. The main hypothesis that I will test is that fungal cell heterogeneity provides subpopulations of cells with greater fitness to resist antifungal treatment. I will determine: (1) which features of three distinct fungal cell types contribute to cell heterogeneity; (2) which cell types and subpopulations of these cells show highest resistance or survival against antifungals; and (3) the roles of septal plugging and cell ploidy in the mechanistic basis of fungal cell heterogeneity. Cutting edge technologies that will be used in this study will include: (1) flow cytometry and fluorescence activated cell sorting (FACS) to identify and select cell subpopulations to test their antifungal resistance, (2) automated, high throughput, high content live cell imaging to analyse the resistance of single cells to antifungals, (3) advanced live-cell imaging techniques including GFP photoactivation and fluorescence recovery after photobleaching (FRAP) to identify septal pore plugging; and (4) laser microdissection to further analyse septal pore plugging. With these advanced techniques I will study the mechanistic basis of fungal resistance mediated by cell heterogeneity. My results will ultimately show how fungal cell heterogeneity impacts fitness against antifungal drugs and they will be the starting point for designing novel antifungal therapies that reduce this fitness.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз